Which company develops and produces Ibrutinib?

Ibrutinib is developed and produced by the American pharmaceutical companyJanssen Pharmaceuticals. Ibrutinib is a prescription medicine used to treat adults with mantle cell lymphoma(MCL) who have received at least one prior therapy. Treatment of adults with chronic lymphocytic leukemia(CLL)/small lymphocytic lymphoma(SLL). Treatment of adult chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) with 17p deletion. Treatment of adults with Waldenström's macroglobulinemia (WM). Treatment of adults with marginal zone lymphoma(MZL)who require oral or injectable medications(systemic treatment) and who have received some type of prior treatment. Treatment of chronic graft-versus-host disease (cGVHD) in adults and children 1 year and older after failure of 1 or more lines of systemic therapy.

Ibrutinibhelps slow the growth of certain blood cancers by fighting cancerous B cells (a type of white blood cell). It does this by blocking Bruton's tyrosine kinase (BTK) signaling. BTK is a protein found on B cells that instructs B cells to stay alive and reproduce. Ibrutinib also blocks the activity of a similar protein called interleukin-2-inducible T (ITK). This action and its ability to block BTK is thought to contribute to cGVHD. Generic drugs are available in Bangladesh, Laos and India, different manufacturers, different specifications, different prices, the price per box is about 1000 to 2000 more. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.